General Information of Drug (ID: DMX4VY9)

Drug Name
isobutyric acid Drug Info
Synonyms isobutyrate
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
6590
ChEBI ID
CHEBI:16135
CAS Number
CAS 79-31-2
TTD Drug ID
DMX4VY9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GLPG0974 DMXO4T8 Abortion JA00 Phase 2 [4]
HL-018 DMT3HKZ Diabetic complication 5A2Y Phase 1 [5]
(S)-4-CMTB DMI12X9 Discovery agent N.A. Investigative [6]
1-methylcyclopropanecarboxylic acid DMDIH07 Discovery agent N.A. Investigative [7]
pentanoic acid DM56RAX Discovery agent N.A. Investigative [8]
trans-2-methylcrotonic acid DMHJM0B Discovery agent N.A. Investigative [7]
AMG7703 DMJ6L9U Discovery agent N.A. Investigative [9]
PMID23589301C1 DMB7TE6 Discovery agent N.A. Investigative [10]
CATPB DMF7TBW Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 9 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
(S)-4-CMTB DMI12X9 Discovery agent N.A. Investigative [11]
1-methylcyclopropanecarboxylic acid DMDIH07 Discovery agent N.A. Investigative [7]
pentanoic acid DM56RAX Discovery agent N.A. Investigative [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Free fatty acid receptor 2 (FFAR2) TT0FYAN FFAR2_HUMAN Agonist [2]
Free fatty acid receptor 3 (FFAR3) TTXDOHN FFAR3_HUMAN Agonist [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1060).
2 Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem. 2003 Jul 11;278(28):25481-9.
3 Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):1045-50.
4 Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic. J Med Chem. 2014 Dec 11;57(23):10044-57.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 226).
6 Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3. J Biol Chem. 2012 Nov 30;287(49):41195-209.
7 Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. J Biol Chem. 2011 Mar 25;286(12):10628-40.
8 The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem. 2003 Mar 28;278(13):11312-9.
9 Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator. Mol Pharmacol. 2011 Jul;80(1):163-73.
10 Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. J Biol Chem. 2013 Jun 14;288(24):17296-312.
11 Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. Mol Pharmacol. 2008 Dec;74(6):1599-609.